Two Quality Compounders, Two Different Discounts: Neurocrine Biosciences and Uber
Two quality compounders trading on two different worries: Neurocrine Biosciences and Uber
Tickers: NBIX (NASDAQ) · UBER (NYSE) | Price at writing: NBIX $175.77 · UBER $75.95 | Analyst consensus: NBIX Buy, mean target ~$192–196 (11.7–11.9% upside) · UBER mixed, average target ~$105 with a wide $73–150 spread
I. Executive summary
We are pairing two names that have nothing in common operationally and everything in common structurally: both are compounding cash flow at a rate the market is not fully paying for, and both carry a single, well-defined overhang that explains the discount. Neurocrine Biosciences grew revenue 39% year-over-year in Q2 2026 on a debt-free balance sheet and just raised guidance for the second time this year, yet trades at a market cap of roughly $12.4B against a franchise generating close to $900M of trailing free cash flow — the overhang is a DOJ civil investigative demand into INGREZZA marketing practices and integration risk on the $2.9B Soleno acquisition. Uber crossed $10B of trailing twelve-month free cash flow for the first time in its history, expanded operating margin to 13.3%, and is returning at least half of that cash flow to shareholders via a newly authorized $20B buyback — yet the stock sits roughly 25–34% below its 2026 high because the market is pricing an existential threat from Waymo- and Tesla-led robotaxi competition that has not yet shown up in a single quarter of Uber's actual numbers. Our view: NBIX is the higher-quality, lower-controversy compounder and the more straightforward long; UBER is the higher-torque, higher-controversy compounder where the AV overhang is a real risk but is currently being priced as a near-certainty rather than a probability-weighted outcome.
II. The setup — why this matters now
Both names reported Q2 2026 in the first week of August, both beat on the metric that mattered most to their bull case, and both stocks have done almost nothing since. INGREZZA — the tardive dyskinesia and Huntington's chorea drug that is still roughly three-quarters of NBIX's revenue — posted record new-patient additions and 15% net sales growth even as a legacy franchise, which is the opposite of what happens to most drugs seven years post-launch. CRENESSITY, launched into congenital adrenal hyperplasia, is scaling faster than INGREZZA did at the same stage. Uber, meanwhile, posted 24% gross bookings growth against a 12% revenue growth number — the gap is bookings taking share while advertising and other high-margin lines grow underneath it, which is precisely the mix shift that should re-rate the multiple over time, and Uber closed the quarter by formally committing over $10B toward AV scale-up so it can sit on both sides of the disruption instead of just the losing one.
The reason both have stalled is that markets in August 2026 are unusually allergic to any name with an open regulatory question (NBIX) or an open existential-competition question (UBER), regardless of what the trailing numbers say. That is a sentiment problem, not (yet) a fundamentals problem, and sentiment problems on names with real cash flow are exactly the setup we look for.
III. The thesis
NBIX — Neurocrine Biosciences
The core franchise is still accelerating, not maturing. INGREZZA revenue guidance has been raised twice in 2026, most recently to $2.825B–$2.875B for the full year, roughly 13% growth at the midpoint on a drug that has been on the market since 2017. Management attributes this to record new-patient starts, not price — the durable kind of growth.
CRENESSITY is a legitimate second leg, not a rounding error. $184M in Q2 sales for a drug still in launch phase is a strong trajectory, and it de-risks the long-running “one-drug company” bear case that has capped NBIX's multiple for years.
The balance sheet gives real optionality. Zero total debt against $3.4B of shareholder equity means the Soleno acquisition — even at $2.9B in cash — does not require NBIX to take on leverage, and it means the company can absorb the DOJ inquiry's legal costs without any liquidity stress.
The market is pricing the DOJ inquiry as an unknown, not as a number. Civil investigative demands into pharma sales and marketing practices are common, resolve over years rather than quarters, and historically end in fines that are immaterial relative to franchise cash flow. Until there is a specific number attached, we treat this as a discount-rate problem rather than a thesis-breaking one.
Valuation is not demanding for the growth on offer. A ~37x trailing P/E against 39% revenue growth and a debt-free balance sheet is not cheap in isolation, but it is inexpensive relative to the growth rate and relative to where sell-side targets already sit — the Street's own numbers (Goldman $213, Bernstein $221) imply the market has not caught up to its own analysts.
UBER — Uber Technologies
The cash flow inflection is real and now. Trailing twelve-month free cash flow crossing $10B for the first time is not a projection — it already happened, in the same quarter the stock was falling on AV headlines. GAAP operating margin expanding from 11.5% to 13.3% year-over-year is the kind of operating leverage that shows a platform business, not a subsidized one.
Advertising is the highest-margin lever and it is compounding fastest. Advertising revenue growing 50% year-over-year to a $2.5B annualized run-rate is small in absolute terms today but structurally important — it is the pure-margin layer stacked on top of the marketplace, the same playbook that re-rated Amazon's advertising business a decade ago.
Uber's AV strategy is aggregation, not a bet against Waymo. Rather than building its own AV stack and racing Waymo and Tesla on hardware, Uber has signed on roughly 120,000 committed vehicles across AV partners and is targeting 15+ cities by year-end, positioning itself as the demand-side layer regardless of which hardware provider wins.
Capital return is now explicit policy, not a promise. Management has stated at least half of forward cash flow generation goes to buybacks, backed by a $20B authorization on top of the original $7B.
The freight segment is the one real soft spot. Freight bookings grew 25% but the segment still posted a $24M operating loss — worth monitoring, but it is a small piece of the overall business.
The bear case has a real mechanism, and we are not dismissing it. If AVs from Waymo, Tesla, or another vertically integrated player scale faster than Uber's aggregation model can capture demand, Uber's take-rate economics erode from the supply side. Melius Research's January 2026 downgrade to a $73 target and Daiwa's more recent downgrade to Neutral reflect a plausible outcome. Our disagreement is with the probability being priced, not the existence of the risk.
IV. By the numbers
NBIX
Q2 2026 total revenue: $959M, +39% YoY (SEC 8-K, 2026-08-03)
INGREZZA Q2 net sales: $716M, +15% YoY
CRENESSITY Q2 net sales: $184M
VYKAT XR (from Soleno, closed 18 May 2026): $54M recognized by NBIX in Q2 on a $94M pro forma basis
FY2026 INGREZZA guidance: raised to $2.825B–$2.875B from $2.7B–$2.8B (~13% YoY at midpoint)
Total debt: $0.0B · Shareholder equity: $3.4B · Debt-to-equity: 0%
TTM free cash flow (through Q1 2026): $831.3M, +72.4% YoY
Market cap: ~$12.4B · Trailing P/E: ~37.0x
Analyst ratings: 23 Buy, 3 Hold, 0 Sell · Mean target ~$192–196, range $160–$249
Soleno acquisition: $2.8B definitive agreement (announced 5 April 2026) at $53/share, ~34% premium
UBER
Q2 2026 revenue: $14.2B, +12% YoY (investor.uber.com, 2026-08-05)
Gross Bookings: $58.0B, +24% YoY
Mobility Gross Bookings: $29.0B, +22% YoY · Delivery: $27.5B, +26% YoY · Freight: $1.6B, +25% YoY (segment operating loss: $24M)
Advertising revenue: +50% YoY, ~$2.5B annualized run-rate
Non-GAAP EPS: $0.81, +35% YoY
GAAP operating income: $1.9B, +30% YoY · GAAP operating margin: ~13.3%, up from ~11.5%
Free cash flow: $2.8B for the quarter · TTM free cash flow: >$10B for the first time
Share repurchases: $518M in Q2 2026 · new $20B authorization on top of the original $7B (2024)
AV commitment: >$10B planned over coming years · ~120,000 vehicles committed by AV partners across the network
Total debt (incl. capital leases): ~$12.2B (Q1 2026) · Debt-to-equity: ~0.39x
Market cap: ~$154.6B · Price: $75.95, down from a 2026 high of $101.99
Analyst consensus: mixed · average target ~$105 · bear targets as low as $73 (Melius, Jan 2026)
V. Risks and what would change our mind
NBIX
A DOJ finding with a materially large fine or a marketing-practices consent decree that constrains INGREZZA promotion would be a genuine negative catalyst, not a sentiment one. We would revisit the thesis if the CID escalates to a formal complaint.
Soleno integration underperforms and VYKAT XR growth stalls post-acquisition — watch the next two quarters of pro forma VYKAT XR sales against the $94M pro forma baseline.
Customer concentration: three customers were 87% of Q1 2026 gross product sales. A disruption at any one distributor is a real single-quarter risk, even if not a thesis-breaking one.
Austedo (Teva) continues to compete hard in tardive dyskinesia; NBIX's own head-to-head occupancy data is a defense, not a guarantee of continued share.
UBER
If Waymo and/or Tesla scale robotaxi supply faster than Uber's aggregation model can integrate it, and captures demand directly rather than through Uber's marketplace, the multiple compression the bears are pricing becomes justified rather than premature. Watch city-count and vehicle-commitment progress against the 15+ cities / 120,000-vehicle targets.
Freight's operating loss, while small, needs to trend toward breakeven; a widening loss would be a signal of poor capital discipline outside the core.
Regulatory risk around driver classification remains a background risk across every major market Uber operates in and was not resolved by anything in this quarter's print.
What would change our mind on either name: for NBIX, a DOJ complaint with quantified penalties or a stalled Soleno integration by Q1 2027. For UBER, AV partners taking direct-to-consumer share inside Uber's own markets rather than routing through the Uber app, or Freight's loss widening for two consecutive quarters.
VI. Implications for portfolios
We view NBIX as the more defensible, lower-controversy compounder for a core healthcare allocation — debt-free, accelerating, with a regulatory overhang that is real but historically resolves as a cost-of-doing-business rather than a franchise-ending event. We view UBER as the higher-conviction, higher-torque idea for investors willing to underwrite the AV debate directly: the cash flow and margin inflection are already in the reported numbers, the capital return policy is explicit, and the stock is pricing a disruption scenario that has not yet appeared in a single quarter of segment data. Position sizing should reflect that UBER's outcome distribution is wider than NBIX's — this is a name where being early to a re-rating requires tolerating headline risk on every AV story cycle between now and whenever the market gets more data.
VII. What we're watching
NBIX: any update on the DOJ civil investigative demand; Q1 2027 pro forma VYKAT XR sales; INGREZZA new-patient-start trends into year-end.
UBER: AV city-count and committed-vehicle progress against the 15+ cities / 120,000-vehicle targets; Freight segment operating loss trend; pace of the $20B buyback execution; advertising run-rate trajectory past $2.5B.
Both: Q3 2026 earnings, expected early November.
This research is for educational purposes. Not investment advice. The Financial View operates a virtual $100,000 portfolio for educational tracking.
Sources: Neurocrine Biosciences Q2 2026 8-K · RTT News · StockTitan · MarketBeat · Uber Q2 2026 results (investor.uber.com) · Crypto Briefing · Investing.com · Seeking Alpha · TipRanks
